CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...7778798081828384858687...39323933»
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial completion date, Trial primary completion date:  LyRICX: Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer (clinicaltrials.gov) -  Jul 31, 2024   
    P2,  N=320, Recruiting, 
    Trial completion date: Aug 2024 --> Jul 2026 | Trial primary completion date: Aug 2024 --> Jul 2025
  • ||||||||||  EDP1503 / Evelo Biosci, Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment closed, Metastases:  Pembrolizumab and EDP1503 in Advanced Melanoma (clinicaltrials.gov) -  Jul 31, 2024   
    P2,  N=8, Active, not recruiting, 
    Trial completion date: Aug 2024 --> Jul 2026 | Trial primary completion date: Aug 2024 --> Jul 2025 Suspended --> Active, not recruiting
  • ||||||||||  Trial primary completion date, Head-to-Head, Metastases:  Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy (clinicaltrials.gov) -  Jul 30, 2024   
    P3,  N=3, Active, not recruiting, 
    Trial primary completion date: Jun 2024 --> Oct 2024 Trial primary completion date: Jul 2026 --> Jun 2024
  • ||||||||||  sunitinib / Generic mfg.
    Review, Journal, Adverse events:  Immunotherapy for renal cell carcinoma: New therapeutic combinations and adverse event management strategies: A review. (Pubmed Central) -  Jul 30, 2024   
    Future research on the prevention of adverse events and medication resistance related to newer therapies may aid in ensuring effective treatment outcomes among patients with RCC. This article aims to summarize innovative immunotherapy drug combinations for RCC treatment and the mechanisms of action, drug resistance, and treatment of adverse events associated with these combinations.
  • ||||||||||  sunitinib / Generic mfg.
    Journal, Metastases:  Pneumatosis cystoides intestinalis induced by sunitinib therapy in a patient with metastatic renal cell carcinoma: A case report. (Pubmed Central) -  Jul 30, 2024   
    This article aims to summarize innovative immunotherapy drug combinations for RCC treatment and the mechanisms of action, drug resistance, and treatment of adverse events associated with these combinations. This case emphasizes that the decision between conservative versus surgical treatment for PCI should be based not solely on radiological findings but rather on a comprehensive assessment, including the underlying condition, vital signs, physical examinations, and blood tests.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Journal:  Safety and effectiveness of disease-modifying therapies after switching from natalizumab. (Pubmed Central) -  Jul 30, 2024   
    Mean drug survival favored rituximab/ocrelizumab or alemtuzumab over fingolimod (p < 0.001). Our study shows superior effectiveness of rituximab/ocrelizumab and alemtuzumab compared with fingolimod in stable patients switching from NTZ due to JC virus antibody positivity.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, Metastases:  Extended survival in a case of metastatic choroidal melanoma with immunotherapy. (Pubmed Central) -  Jul 30, 2024   
    Ipilimumab and nivolumab are ICIs targeting the cytotoxic T-lymphocyte-associated antigen-4 and the programmed-cell death protein-1, respectively. Herein, we present a case of choroidal melanoma having liver metastasis treated with nivolumab and ipilimumab and transarterial radioembolization, achieving a 3-year survival.
  • ||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin
    Retrospective data, Journal:  Uso de romiplostim en trombocitopenia inmunitaria: experiencia en Cuenca (Ecuador) (Pubmed Central) -  Jul 30, 2024   
    Herein, we present a case of choroidal melanoma having liver metastasis treated with nivolumab and ipilimumab and transarterial radioembolization, achieving a 3-year survival. Romiplostim constituye un tratamiento de segunda l
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Journal:  A Comprehensive Study on Aberrant CD20-Positive Mycosis Fungoides: Clinical and Prognostic Insights. (Pubmed Central) -  Jul 30, 2024   
    This study provides important insights into the clinical attributes, disease progression, and treatment options for MF patients with aberrant CD20 expression. Further research is necessary to validate the effectiveness of emerging therapies and enhance our understanding of the underlying mechanisms and prognostic determinants specific to this unique MF subgroup.
  • ||||||||||  sunitinib / Generic mfg.
    Journal:  Design, synthesis, anti-cancer, anti-inflammatory and in silico studies of 3-substituted-2-oxindole derivatives. (Pubmed Central) -  Jul 30, 2024   
    Key residues such as Glu917, Cys919, Lys920, Glu850, Lys838, and Asp1046 were found to play critical roles in ligand binding and kinase inhibition, providing valuable insights for designing potent VEGFR2 inhibitors. The quantum mechanics-based independent gradient model analysis further highlighted the electronic interaction landscape, showing larger attractive peaks and higher electron density gradients for compounds 4d and 4e compared to Sunitinib, suggesting stronger and diverse attractive forces.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Journal:  TEMPI syndrome: difficult to diagnose, "easy" to treat? (Pubmed Central) -  Jul 30, 2024   
    We also report preliminary data on a multiplex assay for cytokines and growth factors for two patients with TEMPI syndrome and note lower levels for non-specific innate immunity related cytokines. A direct link between renal impairment and TEMPI syndrome is not currently established; cytokine deregulation could potentially be involved in the ischemic changes observed in the renal biopsy of our patient.
  • ||||||||||  Rituxan (rituximab) / Roche
    Review, Journal, Video:  Unique endoscopic features of primary biliary diffuse large B-cell lymphoma: A case report with literature review (with video). (Pubmed Central) -  Jul 30, 2024   
    After six courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, positron emission tomography-computed tomography showed the disappearance of 18-fluorodeoxyglucose uptake in the bile duct and endoscopic retrograde cholangiography showed improvement of the bile duct stricture. Endoscopic findings and repeated biopsies were useful in making the diagnosis of primary biliary diffuse large B-cell lymphoma.
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case. (Pubmed Central) -  Jul 30, 2024   
    Tumor-free surgical margins (R0) resection of patients with advanced ICC after combination of immune, targeted and chemotherapy is rare, and there are almost no cases of complete postoperative remission. The GEMOX regimen in combination with Tislelizumab and Lenvatinib has a good antitumor efficacy and safety profile, and may be a feasible and safe translational treatment option for advanced ICC.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Palbociclib and Fulvestrant Combined Regimen Induced Prolonged Bone Metastasis Control of Stage IV HR+/HER2- Breast Cancer: A Case Report. (Pubmed Central) -  Jul 30, 2024   
    The patient was started on therapeutic doses of letrozole and zoledronic acid in conjunction with adjuvant radiotherapy...A decision was made to switch letrozole for tamoxifen which resulted in disease stability...Palbociclib and fulvestrant were started accordingly, yielding a remarkable metabolic response of all bone metastatic lesions (stable disease) after three months of the regimen initiation. The aforementioned stable disease status continued for approximately three years up to this point.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Journal:  Corneal Transplant Rejection Following Durvalumab Therapy in a Patient With NSCLC: A Case Report. (Pubmed Central) -  Jul 30, 2024   
    Six months after an initially stable post-transplant course, he developed progressive visual decline culminating in graft failure 1 year later despite treatment with prednisone eye drops. This case adds to the limited evidence implicating immune checkpoint inhibitors (ICIs) in corneal graft rejection, emphasizing the need for multidisciplinary evaluation and close monitoring of corneal transplant recipients undergoing ICI therapy.
  • ||||||||||  Izcargo (pabinafusp alfa) / JCR Pharma
    NEUROCOGNITIVE DEVELOPMENTS IN SIBLINGS WITH NEUROPATHIC MPS-II RECEIVING CONVENTIONAL AND NOVEL ENZYME REPLACEMENT THERAPIES: AN UPDATE (Poster Room | Level 0) -  Jul 30, 2024 - Abstract #SSIEM2024SSIEM_488;    
    Two drugs that can address these problems, pabinafusp alfa (PA) for BBB-penetrating intravenous ERT, and idursulfase beta for intracerebroventricular (ICV) ERT, were approved in 2021 for general use in Japan... These observations suggest that novel ERT is clinically effective in addressing neuronopathy in MPS II and helping maintain or improve neurocognitive development, especially when introduced as early as feasible following diagnosis.
  • ||||||||||  lepunafusp alfa (JR-171) / JCR Pharma
    NEUROBEHAVIOURAL AND SOMATIC IMPROVEMENTS OBSERVED IN MPS I PATIENTS TREATED WITH LEPUNAFUSP ALFA (JR-171): REPORT OF FOUR CASES. (Poster Room | Level 0) -  Jul 30, 2024 - Abstract #SSIEM2024SSIEM_470;    
    These observations suggest that novel ERT is clinically effective in addressing neuronopathy in MPS II and helping maintain or improve neurocognitive development, especially when introduced as early as feasible following diagnosis. Along with the findings on the somatic efficacy of JR-171 in its phase 1/2 study, the observed neurobehavioural changes may suggest potential benefits of the drug on neuronopathy that requires further evaluation.
  • ||||||||||  Izcargo (pabinafusp alfa) / JCR Pharma
    GENE THERAPY FOR GM1 GANGLIOSIDOSIS MEDIATED BY AAV VECTOR CARRYING BBB-PENETRABLE ENZYME (Poster Room | Level 0) -  Jul 30, 2024 - Abstract #SSIEM2024SSIEM_443;    
    We concluded that fusion enzyme expressed in the liver was secreted into the blood and efficiently penetrated the brain, resulting in the normalization of the accumulated GM1 ganglioside in the CNS, improvement of neurological function, and extension of lifespan in GM1 mice. Therefore, i.v. of T?gal is an effective approach for the treatment of GM1 at a low viral dose.
  • ||||||||||  Kineret (anakinra) / SOBI, Rituxan (rituximab) / Roche
    EXPANDING THE PHENOTYPE OF METHYLENE TETRAHYDROFOLATE DEHYDROGENASE 1 DEFICIENCY (MTHFD1) (Poster Room | Level 0) -  Jul 30, 2024 - Abstract #SSIEM2024SSIEM_398;    
    Inflammation and dysregulation of the immune response have not previously been associated with MTHFD1 deficiency. Given the number of cases reported in the literature, it is likely that we have yet to elucidate the full clinical spectrum of this disorder.
  • ||||||||||  Opdivo (nivolumab) / BMS
    Biomarker, Trial completion date, Trial primary completion date, Combination therapy:  Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) -  Jul 30, 2024   
    P2,  N=40, Active, not recruiting, 
    Trial completion date: Mar 2026 --> Jul 2024 | Active, not recruiting --> Terminated; The sponsor is no longer supporting the drug Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Apr 2026
  • ||||||||||  Nubeqa (darolutamide) / Bayer, Orion Corp, Verzenio (abemaciclib) / Eli Lilly
    Trial primary completion date:  Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer (clinicaltrials.gov) -  Jul 29, 2024   
    P1/2,  N=93, Active, not recruiting, 
    Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Apr 2026 Trial primary completion date: Jul 2024 --> Jul 2025